The Treat Trial-moving ST-elevation myocardial infarction care forward, with more to do

Clyde W. Yancy; Robert A. Harrington

doi:10.1001/jamacardio.2018.0612

The Treat Trial-moving ST-elevation myocardial infarction care forward, with more to do

Clyde W. Yancy^*, Robert A. Harrington

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Editorial › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	399-400
Number of pages	2
Journal	JAMA cardiology
Volume	3
Issue number	5
DOIs	https://doi.org/10.1001/jamacardio.2018.0612
State	Published - May 2018

Funding

Dr Harrington reports receiving grants from Astra, Bristol-Myers Squibb, Janssen, Novartis, Portola, the Medicines Company, Sanofi, and CSL Limited; personal fees from Amgen, Bayer, Element Science, Gilead, MyoKardia, and the Medicines Company; and serving on the board of directors of the American Heart Association and Stanford Health Care. No disclosures were reported.

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1001/jamacardio.2018.0612

Cite this

@article{36da7237a5ab4f18aa1ba70e77696240,

title = "The Treat Trial-moving ST-elevation myocardial infarction care forward, with more to do",

author = "Yancy, {Clyde W.} and Harrington, {Robert A.}",

note = "Funding Information: Dr Harrington reports receiving grants from Astra, Bristol-Myers Squibb, Janssen, Novartis, Portola, the Medicines Company, Sanofi, and CSL Limited; personal fees from Amgen, Bayer, Element Science, Gilead, MyoKardia, and the Medicines Company; and serving on the board of directors of the American Heart Association and Stanford Health Care. No disclosures were reported.",

year = "2018",

month = may,

doi = "10.1001/jamacardio.2018.0612",

language = "English (US)",

volume = "3",

pages = "399--400",

journal = "JAMA cardiology",

issn = "2380-6583",

publisher = "American Medical Association",

number = "5",

}

TY - JOUR

T1 - The Treat Trial-moving ST-elevation myocardial infarction care forward, with more to do

AU - Yancy, Clyde W.

AU - Harrington, Robert A.

N1 - Funding Information: Dr Harrington reports receiving grants from Astra, Bristol-Myers Squibb, Janssen, Novartis, Portola, the Medicines Company, Sanofi, and CSL Limited; personal fees from Amgen, Bayer, Element Science, Gilead, MyoKardia, and the Medicines Company; and serving on the board of directors of the American Heart Association and Stanford Health Care. No disclosures were reported.

PY - 2018/5

Y1 - 2018/5

UR - http://www.scopus.com/inward/record.url?scp=85049083789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049083789&partnerID=8YFLogxK

U2 - 10.1001/jamacardio.2018.0612

DO - 10.1001/jamacardio.2018.0612

M3 - Editorial

C2 - 29525822

AN - SCOPUS:85049083789

SN - 2380-6583

VL - 3

SP - 399

EP - 400

JO - JAMA cardiology

JF - JAMA cardiology

IS - 5

ER -

The Treat Trial-moving ST-elevation myocardial infarction care forward, with more to do

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this